Fig. 5: Evaluation of bispecific antibody format in cell-based functional assay. | Oncogene

Fig. 5: Evaluation of bispecific antibody format in cell-based functional assay.

From: A multi-faceted discovery strategy identifies functional antibodies binding to cysteine-rich domain 1 of hDKK1 for cancer immunotherapy via Wnt non-canonical pathway

Fig. 5

A SC52-001 and SC52-005 bind to DKK1 CRD1 and elicit immune cell activation, while SC52-2 binds to DKK1 CRD2 and activates Wnt signaling. Bispecific antibodies consisting of a combination of SC52-001, 002, or 005 were generated as shown. B The potencies of Wnt signal activation of DKK1 CRD1 binders are increased with bispecific antibody treatment that combine DKK1 CRD2 binders as compared to that of monospecific antibody treatment. C NK cell activation of DKK1 CRD2 binders increased with bispecific antibody treatment that combine DKK1 CRD1 binders as compared to that of monospecific antibody treatment. D, E Tumor cell cytotoxicity effect is upregulated in DKK1 CRD2 binders with bispecific antibody treatment that combine DKK1 CRD1 binders as compared to that of monospecific antibody treatment. All the samples were duplicated, and the assays were repeated twice.

Back to article page